Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.

"Declaration of personal interest : None."

"The data were abstracted by two investigators independently (AVK and PK) based on the protocol priori, which was registered on Prospero (CRD42020181962). Case reports (of >2 patients), case series, cross‐sectional studies, case‐control studies, cohort studies (retrospective and prospective), quasi‐randomised and randomised controlled trials that mentioned elevated liver chemistries in patients with COVID‐19 were included irrespective of age and gestational status. Studies that did not report any data on liver chemistries or underlying CLD were excluded. Furthermore, experimental studies, studies describing the mechanism, review articles, virology studies, studies describing only the radiological features or studies describing the usage of artificial intelligence in COVID‐19, epidemiology, transmission, and surveillance‐related articles, editorials, investigations (testing)‐related articles, guidelines, recommendations, unpublished data and management‐related articles were excluded. The following parameters were recorded: first author country of study, number of patients, age, gender, underlying CLD and their outcomes, percentage of patients with elevated liver chemistries (defined as elevation above the laboratory upper limit of normal) at initial presentation, percentage of patients developing elevated liver chemistries during the illness, number of patients with severe disease/non‐severe disease, and percentage of patients developing drug‐induced liver injury (DILI) and the implicated drug and lastly the mortality if reported."